Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Filament Health Corp N.FH

Alternate Symbol(s):  FLHLF

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral... see more

Recent & Breaking News (NEO:FH)

FILAMENT HEALTH ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire 7 days ago

FILAMENT HEALTH ANNOUNCES ISSUANCE OF COMMON SHARES TO NEGEV CAPITAL INVESTMENTS LIMITED PURSUANT TO ADVISORY AGREEMENT

Canada NewsWire October 4, 2024

FILAMENT HEALTH ANNOUNCES SECOND QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire August 14, 2024

FILAMENT HEALTH ANNOUNCES MAJOR INTELLECTUAL PROPERTY EXPANSION

Canada NewsWire August 13, 2024

Negev Capital Fund One, L.P. Reports Updated Holdings in Filament Health Corp.

Newsfile June 14, 2024

FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES

Canada NewsWire June 12, 2024

FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER

Canada NewsWire June 3, 2024

FILAMENT HEALTH ANNOUNCES WARRANT EXERCISE AND NOTE CONVERSION BY NEGEV CAPITAL AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES TO BENJAMIN LIGHTBURN, CHIEF EXECUTIVE OFFICER

Canada NewsWire June 3, 2024

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

Accesswire May 29, 2024

FILAMENT HEALTH ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire May 14, 2024

FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS

Canada NewsWire May 3, 2024

FILAMENT HEALTH TO DISCUSS ITS DRUG DEVELOPMENT PLATFORM IN FIRESIDE CHAT WITH WATER TOWER RESEARCH ON APRIL 4, 2024 AT 12PM ET

Canada NewsWire April 3, 2024

FILAMENT HEALTH REPORTS Q4 AND YEAR END 2023 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

Canada NewsWire April 2, 2024

FILAMENT HEALTH ANNOUNCES APPOINTMENT OF MICHAEL MESSINGER TO ITS BOARD OF DIRECTORS

Canada NewsWire March 28, 2024

FILAMENT HEALTH ANNOUNCES SHIPMENTS OF BOTANICAL PSILOCYBIN TO FOUR COUNTRIES FOR CLINICAL INVESTIGATION

Canada NewsWire March 19, 2024

FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO ISRAEL

Canada NewsWire February 15, 2024

FDA investigating new psychedelic drug to treat substance abuse

Jonathon Brown January 31, 2024

FILAMENT HEALTH ANNOUNCES FDA OPENING OF INVESTIGATIONAL NEW DRUG APPLICATION FOR SUBSTANCE USE DISORDERS

Canada NewsWire January 31, 2024

FILAMENT HEALTH COMPLETES THE FIRST EXPORT OF BOTANICAL PSILOCYBIN TO AUSTRALIA

Canada NewsWire January 17, 2024

FILAMENT HEALTH ANNOUNCES CHANGE TO BOARD OF DIRECTORS

Canada NewsWire January 2, 2024